Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
SEATTLE, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA) (the “Company” or “Kineta”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in...
-
Expanded analyses from robust Phase 1 INTERCEPT-AD trial exploring novel target engagement (dose-related), amyloid plaque reduction, and ARIA levels observed with ACU193 administration to be included...
-
ZUG, Switzerland, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary...
-
New York, Oct. 04, 2023 (GLOBE NEWSWIRE) -- The global carbon capture and storage market size is predicted to expand at ~15% CAGR between 2023 and 2035. The market is projected to garner a revenue...
-
VANCOUVER, British Columbia, Oct. 04, 2023 (GLOBE NEWSWIRE) -- American Pacific Mining Corp (CSE: USGD / OTCQX: USGDF / FWB: 1QC) (“American Pacific” or the “Company”) is pleased to announce that...
-
GARDEN CITY, N.Y. and HAMILTON, Bermuda, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric...
-
– Presentations to highlight preclinical data supporting combination of KO-2806 with targeted therapies, including TKIs, KRASG12C inhibitors and KRASG12D inhibitors – SAN DIEGO, Oct. 04, 2023 ...
-
Dublin, Oct. 04, 2023 (GLOBE NEWSWIRE) -- The "Non-Life Insurance Market Summary, Competitive Analysis and Forecast, 2018-2027 (Global Almanac)" report has been added to ResearchAndMarkets.com's...
-
New York, Oct. 04, 2023 (GLOBE NEWSWIRE) -- The global forensic technology market size is expected to expand at ~10% CAGR from 2023 to 2035. The market is anticipated to garner a revenue of USD 47...
-
Phase 2 MIRA primary analysis trial results (12-week) for MoonLake’s Nanobody® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology...